Picture [iito] Fighting Customers 650x80px
Document › Details

Edmond de Rothschild Investment Partners. (2/7/18). "Press Release: Edmond De Rothschild Investment Partners Closes EUR 345 Million BioDiscovery 5 Fund".

Region Region EUR(WEST)+AM(NORTH)
Organisations Organisation BioDiscovery 5 Fund (Andera Partners / EdRIP)
  Group Andera Partners (FR)
  Organisation 2 Erytech Pharma S.A. (Euronext Paris: ERYP, Nasdaq: ERYP)
  Group Erytech (Group)
Products Product BioDiscovery 5 Fund (Andera Partners / EdRIP)
Index term Index term LCF Rothschild–SEVERAL: investment, 201802 closing €345m of BioDiscovery 5 fund of EdRIP
Persons Person Nobécourt, Gilles (LCF Rothschild 201105 Partner at EdRIP)
  Person 2 Litzka, Olivier (Andera Partners 202104 Partner Life Sciences + Coordinator DACH before EdRIP + 3i Venture Healthcare)

BioDiscovery, a leading global investor in biotechnology and medical devices, managed by Edmond De Rothschild Investment Partners, announces today that it has closed the subscription period to its fifth fund, raising EUR 345 million (USD 430 million). BioDiscovery 5 surpassed its initial target of EUR 250 million, making it the largest life science and medical device venture fund to be raised in Europe. BioDiscovery 5 includes investments from current and new investors, with investors representing more than 60% of BioDiscovery 4 choosing to reinvest in BioDiscovery 5. Investors comprise mainly funds of funds, insurance and health insurance companies and pension funds.

With BioDiscovery 5, the Edmond De Rothschild Investment Partners team will continue its focused international investments in a balanced portfolio of innovative drug development and medical device companies across all stages of development. Through BioDiscovery 5, the team will lead investments in companies split between biotech and medical devices across Europe and the United States. The fund can invest up to 10% of the fund per company.

Over a period of 17 years, the BioDiscovery team has raised almost EUR 800 million and through BioDiscovery 1, 2, 3 and 4 funds have invested in 57 life science companies, progressively becoming a leading European investor. The team has a strong exit track record with 16 trade sales including Chase Pharmaceuticals, Tobira, Glycovaxyn, Oncoethix, Covagen, Sapiens, Endosense, Vessix Vascular and 18 IPOs including Poxel, Cellnovo, GenKyoTex, Regado, EOS imaging, SuperSonic Imaging, Probiodrug, OncoMethylome Sciences and Cellectis.

BioDiscovery 5 has already made three investments to date: Erytech Pharma (Euronext: ERYP- Nasdaq: ERYP); Complexa Inc.; and LogicBio Therapeutics, Inc.

The BioDiscovery franchise is led by Partners Gilles Nobécourt, Olivier Litzka, Naveed Siddiqi and Raphaël Wisniewski. Its team of eleven professionals brings together extensive life science industry experience, and several decades of private equity and venture capital knowledge.

BioDiscovery was one of the first funds in Europe wholly dedicated to the life sciences, and remains one of the largest, pure-play funds in Europe focused on leading investment in life science companies across the development spectrum. The team brings an impressive global network, and a breadth of experience across the healthcare industry, which makes it an ideal strategic partner to innovative companies, providing both financial and scientific guidance throughout their development.

Record changed: 2021-07-12


Picture EBD Group BIO-Europe 2021 Time to Register 650x200

More documents for Andera Partners (FR)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture [iito] Back into Ad 650x80px

» top